IHH unit withdraws IPO application in India

Agilus submitted its Draft Red Herring Prospectus on 29 September.

Agilus Diagnostics, an indirect subsidiary of IHH Healthcare, has aborted its plan for an IPO in the Securities and Exchange Board of India (SEBI).

In a bourse filing, IHH said its Agilus has received approval to withdraw its Draft Red Herring Prospectus (DRHP) submitted on 29 September for a proposed IPO process through an offer of sale.

IHH cited "commercial conditions" as the reason for the IPO cancellation.

"Agilus would be making the necessary application to SEBI for withdrawal of the said DRHP immediately and may re-file with SEBI again for a proposed IPO in future, subject to applicable laws," IHH said,

Follow the link for more news on

IHH Healthcare

IPO

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia